Skip to main content
Advertisement
Advertisement

VVOS

VVOS logo

Vivos Therapeutics, Inc. Common Stock

0.15
USD
Sponsored
0.00
-2.28%
Sep 24, 15:59 UTC -4
Closed
exchange

Pre-Market

0.14

0.00
-0.34%

VVOS Earnings Reports

Positive Surprise Ratio

VVOS beat 9 of 22 last estimates.

41%

Next Report

Date of Next Report
Nov 17, 2026
Estimate for Q3 26 (Revenue/ EPS)
$5.98M
/
-$0.30
Implied change from Q2 26 (Revenue/ EPS)
+16.09%
/
-3.23%
Implied change from Q3 25 (Revenue/ EPS)
-11.80%
/
-38.78%

Vivos Therapeutics, Inc. Common Stock earnings per share and revenue

On Aug 14, 2026, VVOS reported earnings of -0.31 USD per share (EPS) for Q2 26, beating the estimate of -0.39 USD, resulting in a 21.40% surprise. Revenue reached 5.15 million, compared to an expected 5.47 million, with a -5.86% difference. The market reacted with a -12.26% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 4 analysts forecast an EPS of -0.30 USD, with revenue projected to reach 5.98 million USD, implying an decrease of -3.23% EPS, and increase of 16.09% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
PharmaCyte Biotech, Inc. Common Stock
Report Date
Sep 14, 2026 For Q1 27
Estimate
-
Actual
-$0.54
Surprise
-
FAQ
For Q2 2026, Vivos Therapeutics, Inc. Common Stock reported EPS of -$0.31, beating estimates by 21.4%, and revenue of $5.15M, -5.86% below expectations.
The stock price moved down -12.26%, changed from $0.34 before the earnings release to $0.30 the day after.
The next earning report is scheduled for Nov 17, 2026.
Based on 4 analysts, Vivos Therapeutics, Inc. Common Stock is expected to report EPS of -$0.30 and revenue of $5.98M for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement